SST and pancreatic neoplasm: Strikingly, CAF treatment with a novel pan-somatostatin analog SOM230 (Pasireotide® Novartis) does not directly affect their survival (Supplementary Figure 2), nor the survival of pancreatic cancer cells whether or not they are also exposed to CAF CM (Figure 1D, 1G, bars 4 & 5).